Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in lymphatic endothelial cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16244
Sealed predictions
- TMEM100 in dopamine neurons, braak+0.47 (p 0.197) → +0.36 (p 0.341)receipt 16252
- TMEM100 in oligodendrocytes, braak-0.46 (p 0.212) → +0.13 (p 0.743)receipt 16251
Swarm cases
receipt 16252: TMEM100 in dopamine neurons, braak
- power
- full sample +0.33 (p 0.185, n 18), 95% CI -0.16 to +0.69. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.39 (p 0.107, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.37 (p 0.127, n 18). could be the mix.
- skeptic
- leave-one-out range +0.25 to +0.47, sign flips 0; without severely affected donors +0.33 (p 0.185, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TMEM100 in dopamine neurons.
case closed: nothing better to follow up.
receipt 16251: TMEM100 in oligodendrocytes, braak
- power
- full sample -0.23 (p 0.369, n 18), 95% CI -0.63 to +0.27. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.23 (p 0.369, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.14 (p 0.567, n 18). could be the mix.
- skeptic
- leave-one-out range -0.36 to -0.11, sign flips 0; without severely affected donors -0.23 (p 0.369, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TMEM100 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts